Article Text

Download PDFPDF

926 BAY 2965501: a highly selective DGK zeta inhibitor for cancer immunotherapy
  1. Rienk Offringa1,
  2. Catherine Olesch1,2,
  3. Frederik Cichon1,
  4. Mareike Grees2,
  5. Norbert Schmees3,
  6. Ulrike Roehn3,
  7. Florian Prinz3,
  8. Detlef Stoeckigt3,
  9. Michael Erkelenz3,
  10. Thi Thanh Uyen Nguyen3,
  11. Ulf Boemer3,
  12. Judith Günther2,
  13. Marc Kunze2,
  14. Kirstin Petersen2 and
  15. Dennis Kirchhoff2
  1. 1German Cancer Research Center (DKFZ), Heidelberg, Germany
  2. 2Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany
  3. 3NUVISAN ICB GmbH, Berlin, Germany
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background The second messenger diacylglycerol plays a key role in T-cell receptor (TCR) downstream signaling and T-cell activation. Diacylglycerol kinase zeta (DGKζ) is a lipid kinase that regulates T-cell activation by phosphorylating diacylglycerol to produce phosphatidic acid, thereby acting as a ligand-independent, intracellular immune checkpoint. The inhibition of DGKζ offers the potential to enhance T-cell priming against suboptimal tumor antigens and to overcome multiple immunosuppressive mechanisms in the tumor microenvironment in a TCR engagement-dependent manner. We evaluated the specificity, efficacy, and safety of the DGKζ inhibitor BAY 2965501 in various preclinical in vitro and in vivo studies.

Methods and Results BAY 2965501 is a highly selective, potent human/mouse cross-reactive DGKζ inhibitor. In vitro, BAY 2965501 increased natural killer cell- and T-cell-mediated tumor cell killing and enhanced interleukin 2-induced natural killer cell activation. Importantly, the inhibition of DGKζ by BAY 2965501 was able to overcome inhibitory signals conferred by transforming growth factor beta, prostaglandin E2, and adenosine signaling in T cells. However, BAY 2965501 showed no direct anti-proliferative effects on human tumor cell lines in vitro. Single-cell sequencing of human tumor-infiltrating lymphocytes isolated from primary human tumors revealed high expression of DGKζ specifically in exhausted CD8+ TCR clonotypes, suggesting a potential immunosuppressive role in this T-cell subpopulation. Furthermore, BAY 2965501 effectively enhanced the in vitro anti-tumor reactivity of human T cells expressing tumor-reactive TCRs. In vivo, BAY 2965501 reduced T-cell exhaustion markers, such as programmed cell death receptor 1 and T-cell immunoglobulin mucin 3, and enhanced antiviral T-cell responses in mice chronically infected with lymphocytic choriomeningitis virus. In MB49, F9, and Hepa129 syngeneic mouse tumor models, BAY 2965501 as monotherapy reduced tumor growth when compared with vehicle treatment. Combining BAY 2965501 with an anti-programmed cell death ligand-1 (anti-PDL-1) antibody reduced tumor growth vs anti-PDL-1 monotherapy. Preclinical toxicology studies showed only low-grade gastrointestinal effects, suggesting a tolerable clinical profile.

Conclusions In summary, BAY 2965501 is a highly potent and selective, orally available DGKζ inhibitor. A first-in-human clinical trial of BAY 2965501 in solid tumors is currently enrolling patients (NCT05614102). This study will evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics, and tumor response profile of BAY 2965501.

Acknowledgements Editing support was provided by Rachel Fairbanks, BA (Hons), Complete HealthVizion, IPG Health Medical Communications, and was funded by Bayer AG.

Ethics Approval All animal experiments were conducted in accordance with the German Animal Welfare Law and approved by Berlin authorities (Landesamt für Arbeitsschutz, Gesundheitsschutz und technische Sicherheit Berlin, LAGetSi; code number A0378/12)

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.